论文部分内容阅读
采用ＲＩＡ法测定１５８例胰腺和胆道良、恶性疾病和２０例正常人血清ＣＡ１９－９含量，部分病例同时测定血清ＰＯＡ、ＣＥＡ含量。结果：正常人血清ＣＡ１９－９含量较低（１３．４±１０．１Ｕ／ｍｌ），无一例阳性（＞３７Ｕ／ｍｌ）。胰腺癌和胆管癌ＣＡ１９－９阳性率分别为８４．４％、７３．８％，显著高于良性胰腺疾病组（２０．０％）和良性胆道疾病组（３０．４％）（Ｐ＜０．００５或Ｐ＜０．０１）。上段胆管癌ＣＡ１９－９阳性率也显著高于中、下段胆管癌（Ｐ＜０．０５）。血清ＣＡ１９－９测定对胰腺癌和胆管癌诊断敏感性７９．３％，特异性７９．１％，正确率８４．８％。ＣＡ１９－９、ＰＯＡ、ＣＥＡ联合检测可提高诊断胰腺癌的可用度。
The RIA method was used to determine serum CA19-9 levels in 158 cases of benign and malignant diseases of the pancreas and biliary tract and 20 cases of normal people. Serum POA and CEA levels were measured simultaneously in some cases. Results: Normal serum CA19-9 levels were low (13.4±10.1 U/ml), and none of them was positive (>37 U/ml). The positive rates of pancreatic cancer and cholangiocarcinoma CA19-9 were 84.4% and 73.8%, respectively, which were significantly higher than those in benign pancreatic disease group (20.0%) and benign biliary disease group (30.4%) (P<0. .005 or P<0.01). The positive rate of CA19-9 in the upper bile duct carcinoma was also significantly higher than that in the middle and lower bile duct carcinoma (P<0.05). The sensitivity of serum CA19-9 in the diagnosis of pancreatic cancer and cholangiocarcinoma was 79.3%, specificity was 79.1%, and the correct rate was 84.8%. Combined detection of CA19-9, POA, and CEA can increase the availability of pancreatic cancer.